5.10 USD
▼-0.01-0.20%
盘后 5.12 0.00%
2026-09-16
市值
$74.02M
市盈率
—
EPS
-3.28
股息率
—
52 周区间
3.16 – 11.89
成交量
46.48K
Beta
-0.89
目标价
21.20
52W 低 3.1652W 高 11.89
价格走势
公司简介
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical...